The Effects of Beta-Hydroxybutyrate on the Effects of Beta-Amyloid in Caenorhabditis elegans
ISEF · 2018 Translational Medical Science
Overview
Alzheimer’s disease (AD) currently affects over 5 million people. As this number continues to rise, it becomes increasingly important to study AD and find therapeutic targets. The beta-amyloid peptide Aß is one such target and is widely seen as a key factor in the pathogenesis of AD. In order to further examine the role of Aß, the nematode C. elegans was used as a model organism to study AD. The GMC101 strain expresses human Aß in the body-wall muscles of the nematodes, presumably causing paralysis at 25°C. ß-hydroxybutyrate (BHB) is a naturally produced ketone body that has previously been shown to have neuroprotective properties. Paralysis assays that involved treating GMC101 nematodes with BHB indicated that BB protected the nematodes from paralysis. A concentration of 100 mM was most effective. Western blot analysis reflected that BHB may also lower the concentration of Aß oligomers. These results support the hypothesis that BHB affects the impact of Aß in C. elegans.
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2018
Using Unique Ultrashort Inhibitor Peptide as BETA-Amyloid Modulator in C. elegans
ISEF · 2024
The Effects of Different Diets on Neurological Function; Implications for Alzheimer's and Parkinson's Disease
ISEF · 2016
The Effect of Spermidine on ß-Amyloid Peptide Toxicity in C. elegans: A Model System for Understanding Alzheimer's Disease
ISEF · 2026
The Impacts of Resveratrol and Escherichia coli Dietary Restriction on the Behavioral and Pathological Aspects of Alzheimer's Disease Using Caenorhabditis elegans as a Model
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair